N-Terminal Pro-B-Type Natriuretic Peptide as a Predictor of Adverse Outcomes After Off-Pump Coronary Artery Bypass Surgery: A Prospective Study
N-terminal pro-B-type natriuretic Peptide as a Predictor after Offpump Coronary Artery Bypass Surgery
Keywords:NT-proBNP, off-pump CABG, adverse postoperative outcomes, in-hospital mortality
Background: The strength of association between preoperative natriuretic peptide levels and adverse outcomes after cardiac surgery recently has been studied in different research, but results still are diversely variable.
Methods: Sixty-five consecutive patients undergoing elective off-pump coronary artery bypass grafting prospectively were recruited. Preoperative levels of NTproBNP were measured in venous blood samples collected before induction of anesthesia.
Results: The average age was 57.62 ± 7.21. Of the patients, 86.15% were male. Euro-scoreII averaged 1.76 ± 0.34. The mean preoperative NTproBNP levels were 312.41 ± 329.93 pg/mL. Only two patients died (3%). Three patients required prolonged mechanical ventilation (4.6%). Four patients (6%) suffered from new onset postoperative AF. Five patients (7.6%) had low cardiac output, of which three needed IABP, and four patients (6%) had postoperative myocardial infarction. The mean ICU stay was 3.37 ± 0.84 days, and the mean hospital stay was 6.38 ± 1.3 days. There were no significant differences in preoperative NTproBNP levels in patients who had or didn’t have any of the postoperative complications or in-hospital mortality (P > .05).
Conclusion: Our study showed no significant correlation between preoperative NTproBNP levels and postoperative low cardiac output, atrial fibrillation, postoperative myocardial infarction, length of ICU stay, prolonged mechanical ventilation, length of hospital stay as well as in-hospital mortality following elective off-pump CABG. Therefore, more prospective specific studies are needed to delineate the role of preoperative natriuretic peptides as significant predictors of poor outcomes after CABG surgery.
Akhmedova IA, Kudaiberdiev TZ, Abibillaev DA, et al. 2020. Relationship of preoperative NT-pro-BNP with clinical, perioperative and prognostic markers in cardiacsurgery: Preliminary study results. Heart Vessels Transplant. 4:99-110.
Attaran S, Sherwood R, Desai J, Langworthy R, Mhandu P, John L, El-Gamel A. 2009. Brain natriuretic peptide a predictive marker in cardiac surgery. 9:662-666.
Brynildsen J, Petäjä L, Pettilä V, et al. 2018. The predictive value of NT-proBNP and hs-TnT for risk of death in cardiac surgical patients. Clinical Biochemistry. 53:65-71.
Chen TH, Lin CL, Shih JJ, et al. 2013. Plasma B-type natriuretic peptide in predicting outcomes of elective coronary artery bypass surgery. Kaohsiung Journal of Medical Sciences. 29:254-258.
Cuthbertson BH, Croal BL, Rae D, et al. 2009. N-terminal pro-B-type natriuretic peptide levels and early outcome after cardiac surgery: a prospective cohort study. Br J Anaesth. 103:647-653.
Elíasdóttir SB, Klemenzson G, Torfason B, Valsson F. 2008. Brian natriuretic peptide is a good predictor for outcome in cardiac surgery. Acta Anaesthesiol Scan. 52:182-187.
Emdin M, Passino C, Prontera C, et al. 2004. Cardiac natriuretic hormones, neuroor-mones, thyroid hormones and cytokines in normal subjects and patients with heart failure. Clin Chem Lab Med. 42:627–636.
Fellahi JL, Daccache G, Makroum Y, Massetti M, Gérard JL, Hanouz JL. 2012. The Prognostic Value of B-Type Natriuretic Peptide After Cardiac Surgery: A Comparative Study Between Coronary Artery Bypass Graft Surgery and Aortic Valve Replacement.Journal of Cardiothoracic and Vascular Anesthesia. 26:624-30.
Fellahi JL, Daccache G, Rubes D, Massetti M, Gérard JL, Hanouz JL. 2011. Does Preoperative B-Type Natriuretic Peptide Better Predict Adverse Outcome and Pro-longed Length of Stay Than the Standard European System for Cardiac Operative Risk Evaluation After Cardiac Surgery? J Cardiothorac Vasc Anesth. 25:256-262.
Gaggin and Januzzi. 2013. Biomarkers and diagnostics in heart failure. Biochem Bio-phys Acta. 1832:2442-245.
Gaggin and Januzzi J. 2014. Natriuretic peptides in heart failure syndrome. Clin Lab Med. 34:43-58.
Iwanaga Y, Nishi I, Furuichi S, et al. 2006. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between sys-tolic and diastolic heart failure. Journal of American College of Cardiology. 47:742-748.
Jogia PM., Kalkoff M, Sleigh JW, et al. 2007. NTproBNP secretion and clinical end-points in cardiac surgery intensive care patients. Anaesth Intensive Care. 35:363-369.
Krzych Ł, Szurlej D, Kołodziej T. 2011. Diagnostic accuracy of preoperative NT−proBNP level in predicting short−term outcomes in coronary surgery: a pilot study. Kardiologia Polska. 69:1121–1127.
Litton E and Ho KM. 2012. The use of pre-operative brain natriuretic peptides as a predictor of adverse outcomes after cardiac surgery: a systematic review and meta-analysis. European Journal of Cardio-thoracic Surgery. 41:525-534.
Liu H, Wang C, Liu L, Zhuang Y, Yang X, Zhang Y. 2013. Perioperative application of N-terminal pro-brain natriuretic peptide in patients undergoing cardiac surgery. Journal of Cardiothoracic Surgery. 8:1-5.
Öztekin A, Memetoðlu M, Kutlu R, et al. 2017. The Predictive Value of Preoperative Serum NT-proBNP Levels for the Need for Inotropic Supportin the Postoperative Pe-riod in Patients Undergoing Coronary Artery Bypass Grafting. Cardiovasc. j 9:90-96.
Schachner T, Wiedemann D, Fetz H, Laufer G, Kocher A, Bonaros N. 2010. Influence of preoperative serum N-terminal pro-brain type natriuretic peptide on the postoperative outcome and survival rates of coronary artery bypass patients. Clinics. 65:1239-1245.
Sindhvananda W, Bunpeth C, Chareonkulnawanun N. 2019. N-Terminal Pro-Brain NatriureticPeptide in Post Cardiac Surgery as a Predictor of Ventilator-Weaning Outcomes. Int J AnestheticAnesthesiol. 6:085.
Suc G, Estagnasie P, Brusset A, Procopi N, Squara P, Nguyen LS. 2020. Effect of BNP on risk assessment in cardiac surgery patients,in addition to EuroScore II. Scientific Reports. 10:10865.
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).